



January 02, 2025

To,

National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.

Symbol: NIDAN

Ref: your email dated 31.12.2024 regarding clarification for Financial Results – Nidan.

Subject: Clarification Letter.

Dear Sir/Ma'am,

This is with reference to your email dated 31.12.2024 regarding clarification for financial results of Company published on 10th November, 2023. We wish to submit that the said results have been signed Ms. Tejal Anil Jayakar (DIN:07984686) who is Executive Director of the Company and therefore Ms. Jayakar is authorised to sign the said results.

In Financial results which we have submitted on 10th November, 2023 we have mentioned her designation as 'Director' and now as per directions of your good offices we are submitting the same results with her designation as 'Executive Director'. Please note that there is no any change in results apart from her designation.

We hope that above information is in line with your requirement.

Thanking You,

Yours Sincerely,

For Nidan Laboratories and Healthcare Limited

Tejal Anil Jayakar
Executive Director & CFO
DIN: 07984686



Nidan Laboratories And Healthcare Limited
CIN - L33111MH2000PLC129883

Regd Office: SY No. 294/A H. No. 18, Swapnshilpa, Behind Aarti Apartment, Vartak Road, Virar (W), 401303

Tel No. +91 8975610000; E-Mail:cs@nidanhealthcare.co.in, Website: www.nidanhealthcare.co.in

Statement Of Unaudited Financial Results for the half year ended 30th September 2023

	Particulars	Half Year ended			Rs in lakhs
		30th September 2023	30th September 2022	31st March 2023	Year Ended
		Unaudited	Unaudited	Audited	31st March 2023
					Audited
1	Income				
	a) Revenue from Operations	1,182.44	1,408.86	1,017.73	2,426.59
	b) Other Income	152.30	32.65	300.28	332.93
	Total Income (a+b)	1,334.74	1,441.51	1,318.01	2,759.52
2	Expenses				
	a) Cost of Materials Consumed	47.40	70.03	53.81	123.84
	b) Changes in inventories of Finished Goods, Work in Progress and Stock-in-Trade	16.15	(0.78)	(14.15)	(14.94)
	c) Employee benefit expenses	227.95	215.07	284.81	499.88
	d) Finance Costs	97.69	103.24	119.07	222.31
	e) Depreciation and Amortization expenses	127.52	143.68	166.14	309.82
	f) Other Expenses	557.85	608.09	529.35	1,137.45
	Total Expenses (a to g)	1,074.56	1,139.33	1,139.03	2,278.36
3	Profit before tax	260.18	302.18	178.98	481.16
4	Tax Expenses				
	a) Current Tax	67.98	90.65	39.49	130.14
	b) Deferred Tax Asset/Liability	1.86	(20.29)	17.35	(2.94)
	c) Tax of earlier year	(1.90)	-	-	-
	Total tax expenses	67.93	70.36	56.84	127.20
5	Profit for the period	192.25	231.82	122.14	353.96
	Paid-up equity share capital				
6	(Face value of Rs 10/- per share)	1,390.00	1,390.00	1,390.00	1,390.00
	Earnings Per Share (not annualized)				
	a) Basic EPS	1.38	1.67	0.88	2.55
7	b) Diluted EPS	1.38	1.67	0.88	2.55

Notes:

1) The above Financial Results are reviewed by the audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on 10th November 2023. The Statutory Auditors of the Company carried out limited review of the above financial Results pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulation 2015

2) As per MCA notification dated 16th February 2015, the companies whose shares are listed on SME exchange are exempted from the compulsory requirement of adoption of IND AS. As the company is covered under exempted from the compulsory requirement of adoption of IND AS, the company has not adopted IND AS.

3) The Company does not have different segments and hence segment wise reporting is not applicable to the Company.

4) Figures of the previous period have been regrouped wherever necessary, to correspond with the figures of the current period

For and on behalf of Board of Directors
Nidan Laboratories and Healthcare Limited

Tejal Anil Jayakar
Executive Director
DIN:07984686



Date : 10th November 2023
Place : Virar

Nidan Laboratories And Healthcare Limited
Statement of Unaudited Assets & Liabilities as at 30th September 2023

Rs in lakhs

	Particulars	As at 30th September 2023 (Un Audited)	As at 31st March 2023 (Audited)
I	Equity & Liabilities		
	1. Shareholders' funds		
	Equity Share Capital	1,390.00	1,390.00
	Reserves and Surplus	5,746.09	5,553.84
		7,136.09	6,943.84
	2. Non - Current Liabilities		
	(a) Long - Term Borrowings	428.59	477.49
	(b) Other Long term liabilities	16.74	16.74
	(c) Long Term Provisions	47.61	47.61
		492.94	541.84
	3. Current Liabilities		
	(a) Short - Term Borrowings	996.34	615.50
	(b) Trade Payables	-	-
	(i) Total outstanding due of micro enterprises and small enterprises; and	-	-
	(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	4.29	20.60
	(c) Other Current Liabilities	63.63	53.90
	(d) Short - Term Provisions	195.46	264.58
		1,259.72	954.48
	TOTAL	8,888.75	8,440.16
II	Assets		
	1. Non - Current Assets		
	(a) Property Plant & Equipment and Intangible Assets		
	(i) Property, Plant & Equipments	2,032.52	2,136.62
	(ii) Intangible Asset	2.64	2.64
	(ii) Capital workin progress	-	-
	(b) Non-Current Investments	-	-
	(c) Long - Term Loans and Advances	4,678.49	4,076.05
	(d) Deferred Tax Asset (Net)	46.45	48.30
	(e) Other Non Current Assets	89.09	88.44
		6,849.19	6,352.05
	2. Current Assets		
	(a) Inventories	20.37	36.52
	(b) Trade Receivables	605.30	602.61
	(c) Cash and Cash Equivalents	644.34	841.94
	(d) Short - Term Loans and Advances	482.70	336.18
	(e) Other Current Assets	286.85	270.86
		2,039.56	2,088.11
	TOTAL	8,888.75	8,440.16

For and on behalf of Board of Directors
Nidan Laboratories and Healthcare Limited

Tejal Anil Jayakar
Tejal Anil Jayakar
Executive Director
DIN:07984686



Date : 10th November 2023
Place : Virar

Nidan Laboratories And Healthcare Limited
Statement of Unaudited Cash flow for the half year ended 30th September 2023

Rs in lakhs

Particulars	For the half year 30th September 2023	For the year ended 31st March 2023
	Unaudited	Audited
A - CASH FLOW FROM OPERATING ACTIVITIES		
Profit Before Tax	260.18	481.16
Add/ (less) Adjustment for:		
Interest Income	(144.46)	(288.39)
Interest Expenses	96.22	200.09
Depreciation	127.52	309.82
(Gain)/loss on disposal of property, plant and equipment	-	(26.90)
Operating Profit Before Working Capital Changes	339.46	675.79
Add/ (less): Adjustments for Changes in working capital:		
(Increase) / decrease in Trade Receivable	(2.69)	(66.44)
(Increase)/ decrease in Other Current Assets	(15.99)	(18.49)
(Increase) / decrease in Short Term Loans and Advances	(146.52)	573.89
(Increase) / decrease in Other Non current assets	(0.65)	(15.48)
(Increase) / decrease in Inventories	16.15	(14.94)
Increase / (decrease) in Trade payables	(16.32)	(94.26)
Increase / (decrease) in Long term liability	-	(17.30)
Increase / (decrease) in Other current Liability	9.83	6.71
Increase / (decrease) in Short Term Provision	(69.12)	135.96
Increase / (decrease) in Long term Provisions	-	43.68
Cash Generated from Operations	114.15	1,209.12
Add/ (less) : Direct taxes paid (net of refund received)	(66.08)	(130.14)
Net Cash inflow from Operating Activities	48.08	1,078.98
B - CASH FLOW FROM INVESTING ACTIVITIES		
Acquisition of property, plant and equipment / intangible assets	(25.72)	(66.83)
Proceeds from sale of property, plant and equipment	2.30	72.00
(Increase) / Decrease in Long term loans and advances	(602.44)	(304.15)
Interest received	144.46	288.39
Net cash inflow/(outflow) from investing activities	(481.40)	(10.59)
C - CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds / (repayment) of borrowings (net)	331.94	(836.49)
Interest Expenses	(96.22)	(200.09)
Net Cash inflow/(outflow) flow from Financing Activities	235.72	(1,037)
Net (Decrease) / Increase in Cash and Cash Equivalents (A+B+C)	(197.60)	31.80
Add: Cash and Cash Equivalents at the beginning of the year	841.94	810.14
Cash and Cash Equivalents at the end of the period/year	644.34	841.94

Notes :

Cash and Cash Equivalents at the end of the year consists of cash in hand and balances with banks are as follows :

Particulars	As at 30th September 2023 Unaudited	As at 31st March 2023 Audited
Cash on hand	637.05	823.20
Balances with bank	7.29	18.74
Closing Cash and Cash Equivalents	644.34	841.94

For and on behalf of the Board of Directors
Nidan Laboratories And Healthcare Limited

Tejal Anil Jayakar
Tejal Anil Jayakar
Executive Director
DIN: 07984686



Date : 10th November 2023
Place : Virar

Nidan Laboratories And Healthcare Limited

CIN - L33111MH2000PLC129883

**Regd Office: SY No. 294/A H. No. 18, Swapnshilpa, Behind Aarti Apartment,
Vartak Road, Virar (w), 401303**

Tel No. +91 8975610000, E-Mail : cs@nidanhealthcare.co.in, Website : www.nidanhealthcare.co.in

Statement Of unaudited Financial Results For The Half Year Ended 30th September 2023

Rs in lakhs

S.No.	Particulars	Half Year Ended 30th September 2023 (Unaudited)	Half Year Ended 30th September 2022 (Unaudited)	Half Year Ended 31st March 2023 (Audited)	Year Ended 31st March, 2023 (Audited)
1	Total Income from Operations	1,334.74	1,441.51	1,318.01	2,759.52
2	Net Profit for the period / year (before tax, exceptional and/or extraordinary items)	260.18	302.18	178.98	481.16
3	Net Profit for the period / year before tax (after exceptional and/or extraordinary items)	260.18	302.18	178.98	481.16
4	Net Profit for the period / year after tax (after exceptional and/or extraordinary items)	192.25	231.82	122.14	353.96
5	Profit for the period / year	192.25	231.82	122.14	353.96
6	Paid up Equity Share Capital	1,390.00	1,390.00	1,390.00	1,390.00
7	Reserves (exluding revaluation reserve)	5,746.09	5,502.07	51.77	5,553.84
8	Earnings Per Share (of Rs 10/-each) (not annualized)				
	Basic	1.38	1.67	0.88	2.55
	Diluted	1.38	1.67	0.88	2.55

1) The above is an extract of the detailed format of Annual Financial Results to filed with National Stock Exchange Limited under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchange websites (www.nseindia.com/) and Company's website : www.nidanhealthcare.co.in

**For and on behalf of Board of Directors
Nidan Laboratories and Healthcare Limited**

(Signature)
Tejal Anil Jayakar
Executive Director
DIN:07984686



Date : 10th November 2023
Place : Virar



R. K. CHAPAWAT & CO.

CHARTERED ACCOUNTANTS

Office : 122, Shripal Shopping Center, Near Petrol Pump, Agashi Road, Virar (West) Dist - Palghar : 401303.

Contact : +91-9323791318 / 0250-2513406, **E-mail :** ravindra_chapawat@rediffmail.com

Limited Review Report on unaudited financial results of Nidan Laboratories & Healthcare Limited for the half year ended 30 September 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Nidan Laboratories & Healthcare Limited

1. We have reviewed the accompanying Statement of unaudited financial results of **Nidan Laboratories & Healthcare Limited** ("the Company") for the Half Year ended 30th September 2023 being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 ("Listing Regulations").

2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For R.K Chapawat & Co.
Chartered Accountants
Firm's Registration No. 101708W

Purnima Jain

Purnima Jain
Partner

M. No. 140032

UDIN: - 23140032BGZUKX7385

Place: Virar

Date: 10th November 2023.

